Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta BionicsBBNX +2.31%10 EBIT per Share is $-1.67 as of Mar. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 685 Medical Devices & Instruments companies, Beta Bionics ranks worse than 53.87% on this metric.
Beta Bionics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.67.
During the past 3 years, the average EBIT per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Beta Bionics's EBIT per Share or its related term are showing as below:
BBNX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 6.4 Med: 6.4 Max: 6.4
Current: 6.4
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Beta Bionics was 6.40% per year. The lowest was 6.40% per year. And the median was 6.40% per year.
BBNX's 3-Year EBIT Growth Rate is ranked worse than 53.87% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs BBNX: 6.40
Beta Bionics's EBIT for the
three
months ended in Mar. 2026 was $-24.3 Mil.
Beta Bionics (NAS:BBNX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Beta Bionics EBIT per Share Related Terms
Beta Bionics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Beta Bionics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Bionics (BBNX) has a EBIT per Share of $-1.67 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beta Bionics and its competitors. According to the industry distribution chart, Beta Bionics ranks #369 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 53.9%.
Is Beta Bionics' EBIT per Share too high?
Beta Bionics' current EBIT per Share is $-1.67. Based on the distribution chart, Beta Bionics ranks #369 out of 685 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' EBIT per Share compare to CBLL and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Beta Bionics ranks #369 out of 685 companies for EBIT per Share. This places Beta Bionics in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beta Bionics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Bionics's current EBIT per Share is $-1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current EBIT per Share of $-1.67. The current EBIT per Share is $-1.67. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Beta Bionics (BBNX), the current EBIT per Share is $-1.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score
Get the complete analysis for BBNX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBNX has been successfully added to your 
